#gyncsm ATHENA-MONO volunteers
75% White, 22% Asian.
This will be a problem going forward. Volunteers on trials should represent the demographics of those who get the disease.
FWIW: Ref SEER (Cases per 100K persons)
75% White, 22% Asian.
This will be a problem going forward. Volunteers on trials should represent the demographics of those who get the disease.
FWIW: Ref SEER (Cases per 100K persons)
ATHENA-MONO Progression free survival favors rucaparib over placebo in volunteers with HRD
Monk: Subgroup analyses all point towards benefit to rucaparib
Three-fold higher toxicities seen with ruacaprib...
Like Niraparib, rucaparib shows a benefit to PFS in the first-line setting as maintenance following chemotherapy for ovarian cancer.
FYI: When talking about deaths, realize statistically it's fine to call them "events" but they occur in people so maybe rethink that.
FYI: When talking about deaths, realize statistically it's fine to call them "events" but they occur in people so maybe rethink that.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
